Trecondi 5 g powder for solution for infusion

DRUG4 trials

Sponsors

Assistance Publique Hopitaux De Paris, Fondazione Santobono Pausilipon Onlus, Fondazione Telethon Ets, San Raffaele Hospital, Universitaetsklinikum Tuebingen AöR

Conditions

Acute Myeloid Leukemia (AML)Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 geneEwing SarcomaMyelofibrosisMyleodyplastic Neoplasm/Acute Myeloid Leukemia (MDS/AML) and higher risk MDS

Phase 1

A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.

Not yet recruitingCTIS2024-518972-30-00

Fondazione Telethon Ets, San Raffaele HospitalAutosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

Target: 8Updated: 2025-08-06

Phase 2

FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis : A phase 2 prospective multicentric prospective study

Active, not recruitingCTIS2024-513325-23-00

Assistance Publique Hopitaux De ParisMyelofibrosis

Start: 2021-02-03Target: 28Updated: 2024-07-23

Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.

Not yet recruitingCTIS2024-518912-37-01

Fondazione Santobono Pausilipon OnlusEwing Sarcoma

Target: 60Updated: 2024-12-09

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantation in AML, MDS/AML and higher risk MDS (Vestal)

Not yet recruitingCTIS2025-521372-62-00

Universitaetsklinikum Tuebingen AöRAcute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute Myeloid Leukemia (MDS/AML) and higher risk MDS

Target: 27Updated: 2025-09-23

Related Papers

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

Blood2025-11-03